Table 3.
Responses to therapy of CML-BP.
| Responses at 3 months including alloSCT (N = 134) | Responses at 6 months including alloSCT (N = 112) | Best responses censored alloSCT (N = 123) | Best responses including alloSCT (N = 184) | |
|---|---|---|---|---|
| No response | 34 | 19 | 37 | 47 |
| Return to CML-CP | 12 | 3 | 5 | 5 |
| CHR + PCyR | 29 | 9 | 18 | 11 |
| CCyR or BCR::ABL1 <1% | 11 | 4 | 16 | 12 |
| MMR | 11 | 14 | 15 | 9 |
| MR4 | 4 | 3 | 10 | 11 |
| MR4.5 | 6 | 6 | 7 | 12 |
| MR5 | 6 | 21 | 15 | 77 |
| Deceased | 21 | 33 | ||
| Observation less than 3 resp. 6 months | 20 | 24 | ||
| Not reported | 86 | 104 |
MMR: BCR::ABL1 ≤ 0.1% international scale (IS); MR4: BCR::ABL1 ≤ 0.01% IS; MR4.5: BCR::ABL1 ≤ 0.0032% IS; MR5: BCR::ABL1 ≤ 0.001% IS.
CML-BP chronic myeloid leukemia blast phase, alloSCT allogeneic stem cell transplantation, CML-CP chronic myeloid leukemia chronic phase, CHR complete hematologic response, CCyR complete cytogenetic response, PCyR partial cytogenetic response (Ph + ≤35%), MMR major molecular remission.